Structural basis of the allergenicity to strawberries due to Fra a 1.02

Strawberry fruits are highly valued due to their flavor, aroma, and benefits for human health. Despite this, 30% of the population with food hypersensitivity also shows adverse reactions to strawberry (Franz-Oberdorf et al, 2016). The FaFra a 1 protein family, homologs of the major birch pollen allergen Bet v 1, is involved in this allergenicity to strawberry. By RNAseq we have identified transcripts for 18 members of the FaFra a 1 family (from 1.01 to 1.18) in strawberry fruits. Although expressed in all tissues analyzed, each family member presents a unique pattern of expression, which suggests functional specialization for each FaFra a 1 protein. FaFra a 1.02 (Fra2 from now on) is the most expressed one in red fruits and is also the most allergenic among the family members tested (Muñoz et al. 2010; Franz- Oberdorf et al, 2016). In order to understand the molecular bases of this allergenicity we crystalized Fra2 and obtained its structure by X-ray diffraction. Fra2 showed a very high structural homology to Bet v 1, and we asked whether the two proteins were recognized by the immune system in a similar way. For this, we generated five different mutant versions of Fra2 in sites described as important for allergenicity in Bet v 1 (Fernandes et al, 2016), and studied their potential allergenicity as well as their crystal structures. Three of the mutants had substitutions in loop 4 (E46R, D48R, E46/48A) and the other two facing the cavity (A141F and Q64W). Compared to Fra2, all the mutants showed a significant reduction in their capacity to be recognized by the serum of patients with allergies to Bet v 1, and their crystal structures revealed conformational changes in the Bet v 1- IgG interaction sites. Together, these results support that Fra2 and Bet v 1 have similar allergenic determinants We hope this research will aid in understanding how human IgGs interact with Fra2 and might help in the development of new cultivars with a lesser allergenic potential.Grants BIO2013-44199R and BES-2014-068723 (MINECO). The authors also acknowledge the support by the Plan Propio from University of Malaga, Campus de Excelencia Internacional de Andalucía

Safety evaluation of the food enzyme pullulanase from genetically modified Bacillus subtilis strain NZYM-AK

Publisher PD

Safety evaluation of the food enzyme β-amylase obtained from barley (Hordeum vulgare)

Publisher PD

Safety assessment of biotechnology used in animal production, including genetically modified (GM) feed and GM animals - a review

Since the beginning of the large-scale commercial cultivation of genetically modified (GM) crops in the mid-nineties, it has continuously increased. This has occurred in particular in non-European countries from which these crops may be exported as commodities to Europe and other markets. Before genetically modified organisms (GMO) are allowed onto the market as animal feed and/or food, they have to undergo a regulatory safety assessment as required by the law in many nations, including that of European Union (EU) nations under EU regulations. This safety assessment is based on an internationally harmonized approach of comparative safety assessment, in which the differences identified during the extensive comparison between a GMO and a conventional counterpart serve as basis for a further safety assessment. The GMOs that have been notified for regulatory approval and assessed for their safety as feed and food in the EU have so far been derived from crops and microorganisms. It is expected that in the near future, also several genetically modified (GM) animals may initially reach the market outside the EU. International activities to harmonize the safety assessment of GM animals have already started and have resulted in the issuance of specific guidelines by Codex alimentarius. Moreover, PEGASUS, an EU-funded project, will consider the perceptions, advantages and disadvantages of GM animals, including perspectives from the social-and life-sciences

The StarLink Case: Issues for the Future

The disclosure in September 2000 that StarLink corn had been found in the human food supply putfood biotechnology in the public spotlight and caused concern among consumers and food systemstakeholders alike that a product approved only for animal use could find its way to grocery shelves. TheStarLink experience raises a number of issues that deserve study concerning the current regulatory systemand public policies affecting genetically modified foods. The issues include how to manage allergenicityissues posed by biotech foods at the approval stage. Most of the issues, however, involve post-approvalcontrol of staple food crops that have been genetically modified. It may be increasingly important in thefuture to maintain the identity of genetically modified crops and segregate them from conventional ones,yet neither the grain trading system nor the government regulatory system were designed to ensure this.This paper is the first step in a case study that Resources for the Future is conducting for the PewInitiative on Food and Biotechnology to identify and analyze the regulatory and public policy issuesraised by the StarLink episode. In this paper, we pose questions concerning the adequacy of curent legalauthority, regulatory procedures, and institutional arrangements for post-approval control of biotech foodsthat we intend to analyze in depth during the balance of the study based on interviews and other research.We welcome comment on this paper and the planned study.agricultural biotechnology, food allergens, food regulation, food safety, genetically modified food, grain trading system, StarLinkTM corn

Safety evaluation of a β-amylase food enzyme obtained from wheat (Triticum spp.)

Publisher PD

Safety evaluation of the food enzyme endo-1,4-β-xylanase from genetically modified Aspergillus niger strain XYL

Publisher PD

Development of a protocol that allows safe consumption of the hypoallergenic apple cultivar Santana

The apple (Malus ×domestica) cultivar Santana was shown to have a low allergenicity in a previously reported clinical trial. A protocol was developed to validate these results outside a clinical setting and to market the Santana as a hypoallergenic apple for large-scale consumption. This protocol was designed to ensure safe consumption of the Santana by consumers suffering from apple allergy. We tested the protocol in a pilot in 100 supermarket stores and evaluated in an internet-based survey with 295 respondents. Forty-one percent of the consumers with an apple allergy did not have an allergic reaction to the Santana. Only five percent of the allergic consumers that tried the Santana reported a strong allergic reaction. In concordance with this, the majority (78%) of the mild apple allergic consumers appreciated the Santana. The developed protocol is considered suitable for safe consumption of the Santana providing that information about the possibility of having an allergic reaction among consumers with a mild apple allergy is added to the label

Safety evaluation of the food enzyme β-amylase obtained from soybean (Glycine max) whey

Publisher PD